Prenetics Global Limited (PRE) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $18.01. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is PRE = $36 (+99.9% upside).
Valuation: PRE trades at a trailing Price-to-Earnings (P/E) of -4.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.06.
Financials: revenue is $92M, +50.1%/yr average growth. Net income is $58M (loss), growing at +22.4%/yr. Net profit margin is -63.1% (negative). Gross margin is 53% (+5.3 pp trend).
Balance sheet: total debt is $2M against $175M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 3.01 (strong liquidity). Debt-to-assets is 1.1%. Total assets: $204M.
Analyst outlook: 1 / 1 analysts rate PRE as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
